Research & Drug Development

NW-3509 is an innovative new chemical entity which, similarly to ralfinamide, originates from Newron-s Ion Channel program. It modulates neuronal hyper-excitability and has shown activity in vivo in a broad battery of psychosis, mania, anxiety, cognition and depression animal models.

NW-3509, acting by a different mechanism from current antipsychotics, has the potential to address unmet medical needs in schizophrenia such as cognitive symptoms, negative symptoms, mood disorders,  partial responders, suicidality and co-morbidities such as anxiety and depression.  

Furthermore, NW-3509 has the potential to treat the manic as well as the depressive phase of Bipolar Disorders without inducing sedation.

NW-3509 is currently undergoing IND-enabling studies.